0.00
—
Close of 6 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About eFFECTOR Therapeutics
Its shares trade under the ticker EFTR. It has been listed since 8 January 2021. In the fiscal year to 31 December 2022, it reported revenue of $3.6m and a net loss of $12.9m. At that date it held total assets of $29.1m and shareholders' equity of $3.9m.
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). The company is headquartered in Solana Beach, California. The company went IPO on 2021-01-08. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Jan 2021
- Employees
- 15
- Website
- effector.com ↗
Leadership
Pay as last reported
- Mr. Craig JalbertPresident, Chief Executive Officer, Treasurer, Company Secretary, Director, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- eFFECTOR Therapeutics employs 15 full-time staff members in Solana Beach.
- The company utilizes a selective translation regulation technology platform for discovery.
- Tomivosertib targets the MNK kinase within the eIF4F complex structure.
Weaknesses
- The firm has only 15 employees, limiting operational capacity significantly.
- Zotatifin is currently in Phase 1/2 trials for solid tumors.
- Tomivosertib requires combination therapy with KEYTRUDA for clinical evaluation.
Opportunities
- Tomivosertib is evaluated in a randomized Phase 2b clinical trial.
- KEYTRUDA is an FDA-approved inhibitor of programmed cell death protein 1.
- Zotatifin targets eIF4A, a key component of the eIF4F complex.
Threats
- Metastatic non-small cell lung cancer patients require complex treatment protocols.
- Phase 1/2 trials for zotatifin face standard clinical risks.
- Development of STRIs involves high regulatory scrutiny for oncology drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.